Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives “Buy” Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report published on Friday, Benzinga reports. The firm currently has a $300.00 price objective on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the company. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. HC Wainwright reiterated a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 18th. Bank of America lifted their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, TD Cowen upped their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Six investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $294.50.

Alnylam Pharmaceuticals Stock Up 2.7 %

Shares of Alnylam Pharmaceuticals stock opened at $273.91 on Friday. The company has a 50-day simple moving average of $274.61 and a two-hundred day simple moving average of $226.42. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The stock has a market capitalization of $35.16 billion, a price-to-earnings ratio of -104.55 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The company’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.15 EPS. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -2.74 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares of the company’s stock, valued at $35,632. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Souders Financial Advisors increased its position in shares of Alnylam Pharmaceuticals by 1.0% during the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after acquiring an additional 36 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in Alnylam Pharmaceuticals by 11.1% during the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 57 shares during the last quarter. V Square Quantitative Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 21.9% in the second quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 60 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Alnylam Pharmaceuticals by 54.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 91 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 95.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 103 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.